Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
2020; Cell Press; Volume: 182; Issue: 3 Linguagem: Inglês
10.1016/j.cell.2020.06.008
ISSN1097-4172
AutoresHui Wang, Yuntao Zhang, Baoying Huang, Wei Deng, Yaru Quan, Wenling Wang, Wenbo Xu, Yuxiu Zhao, Na Li, Jin Zhang, Hongyang Liang, Linlin Bao, Yanfeng Xu, Ling Ding, Weimin Zhou, Hong Gao, Jiangning Liu, Peihua Niu, Li Zhao, Zhen Wei, Hui Fu, Shouzhi Yu, Zhengli Zhang, Guangxue Xu, Changgui Li, Zhiyong Lou, Miao Xu, Chuan Qin, Guizhen Wu, George F. Gao, Wenjie Tan, Xiaoming Yang,
Tópico(s)Animal Virus Infections Studies
ResumoThe coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial.
Referência(s)